Bulletin
Investor Alert

Moderna Inc.

NAS: MRNA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Oct 23, 2020, 7:59 p.m.

/zigman2/quotes/205619834/composite

$

70.80

Change

+0.27 +0.38%

Volume

Volume 70,749

Quotes are delayed by 20 min

/zigman2/quotes/205619834/composite

Previous close

$ 70.84

$ 70.53

Change

-0.31 -0.44%

Day low

Day high

$68.80

$72.40

Open

52 week low

52 week high

$15.52

$95.21

Open

Company Description

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therap...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

107.47

Price to Book Ratio

5.60

Enterprise Value to Sales

91.39

Total Debt to Enterprise Value

0.02

Efficiency

Revenue/Employee

72,541.00

Income Per Employee

-619,302.00

Receivables Turnover

2.57

Total Asset Turnover

0.03

Liquidity

Current Ratio

7.89

Quick Ratio

7.89

Cash Ratio

7.71

Profitability

Operating Margin

-906.38

Pretax Margin

-854.88

Net Margin

-853.73

Return on Assets

-28.95

Return on Equity

-38.00

Return on Total Capital

-37.83

Return on Invested Capital

-35.81

Capital Structure

Total Debt to Total Equity

11.57

Total Debt to Total Capital

10.37

Total Debt to Total Assets

8.55

Long-Term Debt to Equity

11.27

Long-Term Debt to Total Capital

10.10

Officers and Executives

Name Age Officer Since Title
Mr. Stéphane Bancel 46 2011 President, Founding CEO & Director
Dr. Stephen Hoge 43 2013 SVP-Corporate Development & New Drug Concepts
Mr. David W. Meline 61 2020 Chief Financial Officer
Mr. Juan Andres 54 2017 Chief Technical Operations & Quality Officer
Dr. Tal Zaks 54 2015 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
10/20/2020 Stéphane Bancel
Chief Executive Officer; Director
8,455   Disposition at $72.05 per share. 609,182
10/19/2020 Tal Zaks
Chief Medical Officer
200   Disposition at $73.81 per share. 14,762
10/19/2020 Tal Zaks
Chief Medical Officer
3,100   Disposition at $73.12 per share. 226,672
10/19/2020 Tal Zaks
Chief Medical Officer
6,005   Disposition at $71.92 per share. 431,879
10/19/2020 Tal Zaks
Chief Medical Officer
5,695   Disposition at $71.24 per share. 405,711
10/19/2020 Tal Zaks
Chief Medical Officer
10,000   Derivative/Non-derivative trans. at $19.15 per share. 191,500
10/19/2020 Tal Zaks
Chief Medical Officer
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
10/16/2020 Stéphane Bancel
Chief Executive Officer; Director
3,600   Disposition at $76.11 per share. 273,996
10/16/2020 Stéphane Bancel
Chief Executive Officer; Director
2,198   Disposition at $75.24 per share. 165,377
10/16/2020 Stéphane Bancel
Chief Executive Officer; Director
5,248   Disposition at $74.17 per share. 389,244
10/15/2020 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $75.48 per share. 754,800
10/14/2020 Stéphane Bancel
Chief Executive Officer; Director
1,000   Gift at $0 per share. 0
10/14/2020 Stéphane Bancel
Chief Executive Officer; Director
9,000   Disposition at $79.81 per share. 718,290
10/13/2020 Stephen Hoge
President
100   Disposition at $80.39 per share. 8,039
10/13/2020 Stephen Hoge
President
700   Disposition at $79.47 per share. 55,629
10/13/2020 Stephen Hoge
President
2,600   Disposition at $78.4 per share. 203,840
10/13/2020 Stephen Hoge
President
1,400   Disposition at $77.82 per share. 108,948
10/13/2020 Stephen Hoge
President
10,200   Disposition at $75.78 per share. 772,956
10/13/2020 Stephen Hoge
President
10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
10/12/2020 Stéphane Bancel
Chief Executive Officer; Director
8,219   Disposition at $73.61 per share. 605,000
10/12/2020 Stephen Hoge
President
1,256   Disposition at $75.38 per share. 94,677
10/12/2020 Stephen Hoge
President
2,735   Disposition at $74.49 per share. 203,730
10/12/2020 Stephen Hoge
President
1,009   Disposition at $73.21 per share. 73,868
10/12/2020 Tal Zaks
Chief Medical Officer
4,279   Disposition at $75.32 per share. 322,294
10/12/2020 Tal Zaks
Chief Medical Officer
7,421   Disposition at $74.5 per share. 552,864
10/12/2020 Tal Zaks
Chief Medical Officer
3,300   Disposition at $73.3 per share. 241,890
10/12/2020 Tal Zaks
Chief Medical Officer
10,000   Derivative/Non-derivative trans. at $19.15 per share. 191,500
10/12/2020 Tal Zaks
Chief Medical Officer
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
10/09/2020 Stéphane Bancel
Chief Executive Officer; Director
400   Disposition at $73.55 per share. 29,420
10/09/2020 Stéphane Bancel
Chief Executive Officer; Director
10,646   Disposition at $72.97 per share. 776,838
10/08/2020 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $73.5 per share. 735,000
10/07/2020 Stéphane Bancel
Chief Executive Officer; Director
1,000   Gift at $0 per share. 0
10/07/2020 Stéphane Bancel
Chief Executive Officer; Director
9,000   Disposition at $71.23 per share. 641,070
/news/latest/company/us/mrna

MarketWatch News on MRNA

  1. Moderna Inc. stock underperforms Friday when compared to competitors

    4:25 p.m. Oct. 23, 2020

    - MarketWatch Automation

  2. Stock Futures Flat After Final Debate Ends

    11:11 p.m. Oct. 22, 2020

    - Connor Smith

  3. Moderna Inc. stock rises Thursday, outperforms market

    4:25 p.m. Oct. 22, 2020

    - MarketWatch Automation

  4. FDA Coronavirus Meeting Aims to Reassure Public

    1:59 p.m. Oct. 22, 2020

    - Bill Alpert

  5. Glaxo Vaccines Target Another Viral Threat

    12:04 p.m. Oct. 22, 2020

    - Bill Alpert

  6. Moderna Inc. stock underperforms Wednesday when compared to competitors

    4:25 p.m. Oct. 21, 2020

    - MarketWatch Automation

  7. Moderna Inc. stock outperforms market on strong trading day

    4:25 p.m. Oct. 20, 2020

    - MarketWatch Automation

  8. Gold scores back-to-back gains, settles at highest in over a week

    3:28 p.m. Oct. 20, 2020

    - Myra P. Saefong

  9. Loading more headlines...
/news/nonmarketwatch/company/us/mrna

Other News on MRNA

  1. Wall Street Breakfast: What Moved Markets

    8:59 a.m. Oct. 24, 2020

    - Seeking Alpha

  2. Top Analyst Reports for Netflix, Lockheed Martin & Zoetis

    4:06 p.m. Oct. 23, 2020

    - Zacks.com

  3. Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase

    12:33 p.m. Oct. 23, 2020

    - Gregory Zuckerman

  4. Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase

    12:33 p.m. Oct. 23, 2020

    - Gregory Zuckerman

  5. FDA getting cold feet on EUA nod for COVID-19 vaccines

    11:25 a.m. Oct. 23, 2020

    - Seeking Alpha

  6. Could the FDA Be Ready to Crash Inovio’s Hopes and Dreams?

    7:45 a.m. Oct. 23, 2020

    - InvestorPlace.com

  7. Covid-19 Vaccines: What’s Coming and When?

    7:06 p.m. Oct. 22, 2020

    - Ana Rivas

  8. New U.S. Coronavirus Cases Surpass 60,000 for Second Day

    6:14 p.m. Oct. 22, 2020

    - Talal Ansari

  9. Time Is Running Out on Inovio as Other Vaccine Candidates Advance

    2:08 p.m. Oct. 22, 2020

    - InvestorPlace.com

  10. Is It Too Late for Novavax to Profit From a Covid-19 Vaccine?

    1:31 p.m. Oct. 22, 2020

    - InvestorPlace.com

  11. The Vaccine Tightrope

    6:05 a.m. Oct. 22, 2020

    - Seeking Alpha

  12. Covid-19 Vaccines to Be Stored Secretly Under Tight Security

    3:48 p.m. Oct. 21, 2020

    - Jared S. Hopkins

  13. Loading more headlines...

At a Glance

Moderna, Inc.

200 Technology Square

Cambridge, Massachusetts 02139

Phone

1 6177146500

Industry

-

Sector

-

Fiscal Year-end

12/2020

Revenue

$60.21M

Net Income

$-514.02M

Employees

830.00

/news/pressrelease/company/us/mrna

Press Releases on MRNA

  1. How to Play These Covid-19 Vaccine Stocks

    7:00 a.m. Oct. 21, 2020

    - Baystreet.ca

  2. Nasdaq 100 Movers: MRNA, VRTX

    10:43 a.m. Oct. 19, 2020

    - MarketNewsVideo.com

  3. The Big Pharma Race – A Chance for Redemption

    10:24 a.m. Oct. 15, 2020

    - IAM Newswire

  4. Covid-19 Stocks in Play: Regeneron, Moderna, and BioNTech

    7:00 a.m. Oct. 14, 2020

    - Baystreet.ca

  5. Nasdaq 100 Movers: FAST, MRNA

    10:23 a.m. Oct. 13, 2020

    - MarketNewsVideo.com

  6. Monday's ETF with Unusual Volume: FXH

    12:06 p.m. Oct. 12, 2020

    - MarketNewsVideo.com

  7. Nasdaq 100 Movers: DXCM, ZM

    10:26 a.m. Oct. 2, 2020

    - MarketNewsVideo.com

  8. Nasdaq 100 Movers: MRNA, SIRI

    11:19 a.m. Oct. 1, 2020

    - MarketNewsVideo.com

  9. Vaccine Updates- Is October a Reachable Goal?

    9:10 a.m. Oct. 1, 2020

    - IAM Newswire

  10. Nasdaq 100 Movers: WDC, MRNA

    10:45 a.m. Sept. 30, 2020

    - MarketNewsVideo.com

  11. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.